Abstract

The present invention relates to GLP-1 and/or glucagon receptor agonists (for example, oxyntomodulin peptide analogs), pharmaceutically acceptable salts thereof, formulations comprising the same, and uses thereof for treating diabetes and/or obesity or associated diseases or disorders.

IPC Classes  ?

• C07K 14/605 - Glucagons
• C07K 1/02 - General processes for the preparation of peptides in solution
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61J 1/05 - Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids

Abstract

Methods and compositions for controlling hyperparathyroidism are disclosed.

IPC Classes  ?

• A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 5/18 - Drugs for disorders of the endocrine system of the parathyroid hormones

Abstract

A method treating and/or preventing vascular calcification can include administering a mixed metal compound to a subject in need thereof.

IPC Classes  ?

• A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
• A61K 33/26 - IronCompounds thereof
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Pediatric and modified release dosage forms of vitamin D compounds, and methods of making and using the same, are disclosed.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/50 - Microcapsules
• A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 5/20 - Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Abstract

Methods and compositions for treating bariatric surgery patients, and for treating or preventing complications associated with such patients, are disclosed.

IPC Classes  ?

• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 3/14 - Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Abstract

Methods of treating the signs and symptoms of Benign Prostatic Hyperplasia (BPH) in a subject by administering at least one tetrahydrocyclopenta[b]indole compound are disclosed. Also disclosed are methods of treating the signs and symptoms of BPH in a subject by administering at least one tetrahydrocyclopenta[b]indole compound in combination with a phosphodiesterase type-5 inhibitor.

IPC Classes  ?

• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61P 13/08 - Drugs for disorders of the urinary system of the prostate

Abstract

Methods for treating vitamin D insufficiency and secondary hyperparathyroidism in patients having CKD comprising administering repeat doses of 25-hydroxyvitamin D are disclosed. The methods comprise administering 25-hydroxyvitamin D in an amount effective to safely raise the patient's serum 25-hydroxyvitamin D level to greater than 90 ng/ml and/or to control the patient's serum ratio of 25-hydroxyvitamin D to 24,25-dihydroxyvitamin D to less than 20.

IPC Classes  ?

• A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a pharmaceutically acceptable salt thereof,and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.

IPC Classes  ?

• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 35/00 - Antineoplastic agents
• A61P 5/20 - Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Abstract

Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61K 31/663 - Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
• A61P 35/00 - Antineoplastic agents
• A61P 3/02 - Nutrients, e.g. vitamins, minerals

Abstract

A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07C 401/00 - Irradiation products of cholesterol or its derivativesVitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3

Goods & Services

Chemicals for use in science and the pharmaceutical industry; chemicals for use in the manufacture of pharmaceuticals, medical preparations and veterinary preparations. Chemical preparations for medical purposes; pharmaceutical and veterinary preparations; magnesium iron hydroxy carbonate or hydrotalcite for pharmaceutical or veterinary purposes; pharmaceutical and veterinary preparations for use in renal dialysis and in the treatment of renal diseases and kidney ailments; phosphate binders for use in the treatment of hyperphosphataemia.

Goods & Services

(1) Phosphate binders for use in the treatment of hyperphosphataemia; magnesium iron hydroxy carbonate or hydrotalcite for medical, pharmaceutical or veterinary purposes; pharmaceutical and veterinary preparations for use in renal dialysis and in the treatment of renal diseases and kidney ailments; pharmaceutical and veterinary preparations for use in treating bone, muscle or kidney diseases and disorders; pharmaceutical and veterinary preparations for the treatment of diabetes; pharmaceutical and veterinary preparations for the treatment of metabolic diseases namely, phosphorous metabolism dysfunction and calcium metabolism dysfunction; pharmaceutical and veterinary preparations for the treatment of endocrinal and neuroendocrinal systems namely, thyroid disease, kidney failure and glandular hypofunction and hyperfunction; pharmaceutical and veterinary preparations for the treatment of the musculosketal system namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains and cartilage injuries; pharmaceutical and veterinary preparations for the treatment of neurological diseases and disorders namely, Alzheimers, dementia, multiplesclerosis, Parkinsons, meningitis and autonomic dysfunction.

Abstract

Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.

IPC Classes  ?

• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 19/00 - Drugs for skeletal disorders
• A61P 35/00 - Antineoplastic agents

Abstract

This invention relates to methods and small molecules having a phosphate group that can be used to inhibit phosphate transport and to treat or prevent diseases that are related to disorders in the maintenance of normal serum phosphate levels.

IPC Classes  ?

• A61K 31/66 - Phosphorus compounds
• A61P 3/00 - Drugs for disorders of the metabolism

Abstract

Methods and compositions for treating bariatric surgery patients, and for treating or preventing complications associated with such patients, are disclosed.

IPC Classes  ?

• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 3/14 - Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Abstract

Pediatric and modified release dosage forms of vitamin D compounds, and methods of making and using the same, are disclosed.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/50 - Microcapsules
• A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 5/20 - Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Abstract

Methods for treating vitamin D insufficiency and secondary
hyperparathyroidism in patients having CKD comprising administering
repeat doses of 25-hydroxyvitamin D are disclosed. The methods comprise
administering 25-hydroxyvitamin D in an amount effective to safely raise
the patient's serum 25-hydroxyvitamin D level to greater than 90 ng/ml and/
or to control the patient's serum ratio of 25-hydroxyvitamin D to
24,25-dihydroxyvitamin D to less than 20.

IPC Classes  ?

• A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a pharmaceutically acceptable salt thereof,and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.

IPC Classes  ?

• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 5/20 - Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 35/00 - Antineoplastic agents